Skip to main content

Advertisement

Table 1 Characteristics of the included studies

From: Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis

Study Intervention Control Country Recruitment period Time from first ischemic event to randomization Stroke subtype at inclusiona Age (mean) Sex (% males) Follow-up
Plehn 1999 [30] Pravastatin 40 mg/day Placebo USA and Canada Dec 1989–Dec 1991 NA Both cardio and non-cardio NA NA 5 years
White 2000 [31] Pravastatin 40 mg/day Placebo Australia and New Zealand June 1990–Dec 1992 NA Both cardio and non-cardio NA NA 6 years
Collins 2004 [32] Simvastatin 40 mg/day Placebo UK July 1994–May 1997 > 6 months Both cardio and non-cardio 66 75% 5 years
Amarenco 2006 [33] Atorvastatin 80 mg/day Placebo World Sept 1998–Mar 2001 1–6 months Non-cardio 63 60% 4 years
Kennedy 2007 [34] Simvastatin 40 mg/day Placebo USA and Canada May 2003–Dec 2006 ≤ 24 h Both cardio and non-cardio 68 48% 90 days
Yakusevich 2012 [35] Simvastatin 40 mg/day No statin Russia 2008–2010 24–48 h Both cardio and non-cardio 66 44% 1 year
Hosomi 2015 [36] Pravastatin 10 mg/day No statin Japan Mar 2004–Feb 2009 1 months–3 years Non-cardio 66 69% 5 years
Ueno 2015 [37] Rosuvastatin 5 mg/day No statin Japan Aug 2011–Sept 2013 ≤ 7 days Non-cardio 71 96% 6 months
Heo 2016 [38] Rosuvastatin 20 mg/day Placebo Korea Aug 2010–June 2013 ≤ 66 h Non-cardio 65 60% 5 or 14 days
Montaner 2016 [39] Simvastatin 40 mg/day Placebo Spain Apr 2009–Mar 2014 ≤ 12 h Both cardio and non-cardio 74 54% 90 days
  1. aCardio cardioembolic ischemic stroke, Non-cardio non-cardioembolic ischemic stroke